Trial Profile
Switch To RItuXimab in MS A phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2015
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms STRIX-MS
- 21 Nov 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 21 Jun 2011 New trial record